应用输尿管镜放置双J管早期治疗输尿管阴道瘘

Objective To evaluate the clinical effect of placing double J stent using a ureteroscope in early managing ureterovaginal fistula.Methods Twenty-eight patients cases with ureterovaginal fistula from 2002 to 2008 were treated early with placing double J stent using a ureteroscope and the clinical data were reviewed.Results Twenty-two of 28 cases were treated and double J stent was placed in them by a uretero-scope and 75% (21/28)of cases were cured.Four of 21 cases were treated twice by a ureteroscope and were cured finally.7 cases with failure ureterovaginal treatment underwent ureterocystostomy and were cured.The follow-up from 6 months to 33 months (average 10.1±6.4 months)showed that all of the 28 cases had been cured and had no urinary fistula.Conclusion Placing double J stent using a ureteroscope is the first choice of operative procedure for the early treatment of ureterovaginal fistula.     

应用输尿管镜放置双J管早期治疗输尿管阴道瘘

Objective To evaluate the clinical effect of placing double J stent using a ureteroscope in early managing ureterovaginal fistula.Methods Twenty-eight patients cases with ureterovaginal fistula from 2002 to 2008 were treated early with placing double J stent using a ureteroscope and the clinical data were reviewed.Results Twenty-two of 28 cases were treated and double J stent was placed in them by a uretero-scope and 75% (21/28)of cases were cured.Four of 21 cases were treated twice by a ureteroscope and were cured finally.7 cases with failure ureterovaginal treatment underwent ureterocystostomy and were cured.The follow-up from 6 months to 33 months (average 10.1±6.4 months)showed that all of the 28 cases had been cured and had no urinary fistula.Conclusion Placing double J stent using a ureteroscope is the first choice of operative procedure for the early treatment of ureterovaginal fistula.     

胞膜（Ecto）-6A8α-甘露糖苷酶

68Aα-甘露糖苷酶是本实验室克隆的eDNA(GenBank的登记号为AF044414)编码的一个新的人α-甘露糖苷酶^[1]。该cDNA长3300bp，其开放阅读框架编码1062个氨基酸的蛋白质。蛋白质的1028～1048aa为穿膜区。6A8α-甘露糖苷酶属Ⅰ型穿膜蛋白。6A8基因定位于第15号染色体q11～13区。     

microRNA在自身免疫性肝炎中的作用机制研究进展北大核心CSCD

自身免疫性肝炎(AIH)是一种慢性炎症性肝病,目前引发和驱动AIH自身免疫性炎症反应、肝内免疫耐受性丧失及炎症调节的机制尚不明确。近年研究表明微小RNA(miRNA)在AIH免疫应答和病程进展过程中具有重要作用,多种miRNA通过与炎症相关通路相互作用调节炎症递质释放,可能成为AIH诊断及治疗的生物标志物,miRNA模拟物或抑制剂和外源性miRNA可能成为AIH新的靶向治疗方法。本文主要综述miRNA在AIH发生发展过程中的研究进展,以期为AIH诊治提供新思路。     

泌尿系结石患者微创术后结石成分分析及饮食干预对结石复发率的影响

目的分析泌尿系结石患者微创术后结石成分及饮食干预对结石复发率的影响。方法将行微创术治疗的60例泌尿系结石患者随机分为两组,各30例。两组术后均采用结石红外光谱自动分析系统分析结石成分,对照组给予常规饮食,观察组根据结石成分给予饮食干预。经1年随访,观察两组结石复发率。结果两组患者结石成分构成基本一致,构成比比较差异均无统计学意义(P>0.05);经1年随访,观察组结石复发率13.33%,低于对照组的36.67%(P<0.05)。结论泌尿系结石微创术后根据结石成分给予患者饮食干预,可明显降低结石复发率。     

1450株支原体耐药性分析

目的了解我院泌尿生殖道感染患者解脲支原体(Uu)和人型支原体(Mh)的感染情况及对9种抗生素的耐药性,为临床治疗支原体感染用药提供参考依据,有效控制支原体感染。方法采用上海奥普生物药业有限公司生产的支原体培养、鉴定药敏一体化的试剂盒进行支原体培养及药敏试验。结果从3 130例患者标本中分离出支原体1 450株,男性患者支原体阳性166例(11.45%),女性患者支原体阳性1 284例(88.55%);其中单纯解脲支原体(Uu)感染1 061例(73.17%);单纯人型支原体(Mh)感染353例(24.34%);Uu/Mh混合感染36例(2.49%)。药敏试验结果显示支原体对多西环素最为敏感。结论支原体对多种抗生素耐药,治疗支原体引起的泌尿系统感染,应以多西环素、交沙霉素、米诺环素作为首选药物。     

443株肺炎克雷伯菌的耐药性分析

目的了解肺炎克雷伯菌对抗生素的耐药情况,为临床合理使用抗生素提供依据。方法对临床各种标本中分离得到的443株肺炎克雷伯氏菌进行药敏试验分析。结果从4 845份送检标本中共分离得到肺炎克雷伯菌443株(9.14%),主要来源于呼吸道标本。肺炎克雷伯菌耐药率最高的抗生素为氨苄西林(94.6%);对氨基糖苷类的阿米卡星耐药率较低,为14.67%;对庆大霉素耐药率为68.79%;对碳青霉烯类抗生素(亚胺培南,美洛培南)全部敏感。在443株肺炎克雷伯菌中,117株为超广谱β-内酰胺酶(ESBLs)阳性,阳性率为26.41%。结论肺炎克雷伯菌是产ESBLs条件致病菌之一,临床应加强对肺炎克雷伯菌耐药性的监测,预防耐药菌株的传播流行。     

膀胱黏膜毒蕈碱型胆碱能受体密度与前列腺术后膀胱痉挛的相关性研究

目的  探讨膀胱黏膜毒蕈碱型胆碱能受体（M受体）M2、M3亚型的密度与前列腺电切术后膀胱痉挛的相关性。方法  选取2012年5月-2015年5月医院收治的良性前列腺增生（BPH）患者作为研究对象,将其分为合并膀胱过度活动症（OAB）观察组和不合并OAB对照组,再将观察组分为发生膀胱痉挛组及不发生膀胱痉挛组,比较各组M2、M3受体的密度及其相关性。结果  观察组术后膀胱痉挛的发生率高于对照组;观察组M2、M3受体密度均低于对照组;观察组中发生膀胱痉挛患者的M3受体密度低于不发生膀胱痉挛患者的M3受体密度。结论  膀胱黏膜M3受体密度与前列腺术后发生膀胱痉挛存在相关性,提示M3受体可能参与膀胱痉挛的发病机制。

     

指按法动力学参数的量化测定与比较分析

目的:通过对不同组别人群指按法动力学参数的量化测定与比较分析,观察其操作是否具有一致性,为指按法的量化与规范化、临床教学提供一定的依据.方法:应用MFF多点薄膜压力测试系统,检测并记录3组不同推拿年限的操作者进行手法操作过程中的动态图形,并保存分析相应的参数数据.结果:3组指按法的平均作用力为本科生组轻度(5.99±2...     

额外侧入路切除鞍结节脑膜瘤

回顾性分析近7年来我院采用额外侧入路显微外科方法切除34例鞍结节脑膜瘤患者的临床资料。结果Simpson脑膜瘤切除I级17例,Ⅱ级14例,Ⅲ级3例。术后出现尿崩、电解质紊乱6例,均于1个月内恢复,1个月垂体功能均基本正常。术后1w视力提高20例,视力无明显变化8例,视力下降6例,3个月后视力较术前提高26例,无明显变化6例,视力下降2例。随访6个月-5年,2例复发再次行手术治疗,其余无肿瘤复发,疗效良好。额外侧入路切除鞍结节脑膜瘤手术疗效良好,可减手术创伤,符合目前倡导的微侵袭理念。